Akebia Announces Dosing of First Patient in Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis
On September 25, 2014, Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and... Read More
High complication rate after total knee and hip replacement due to perioperative bridging of anticoagulant therapy based on the 2012 ACCP guideline.
Leijtens B, Kremers van de Hei K, Jansen J, Koeter S
Arch Orthop Trauma Surg 2014;134:1335-1341.
Review by D. Faraoni
Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial.
Galas FR, de Almeida JP, Fukushima JT, et al.
J Thorac Cardiovasc Surg 2014;148:1647-1655.
Review by D. Faraoni